{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:17:06Z","timestamp":1790410626027,"version":"4.1.0"},"reference-count":51,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T00:00:00Z","timestamp":1598054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,8,16]]},"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec id=\"S2001\">\n                  <jats:title>Objectives:<\/jats:title>\n                  <jats:p>SLE is an autoimmune disease characterised by aberrant lymphocyte activation and autoantibody production. This study provides an in-depth preclinical and clinical characterisation of the treatment effect of cenerimod, a sphingosine-1-phosphate receptor type 1 (S1P<jats:sub>1<\/jats:sub>) modulator, in SLE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"S2002\">\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>Cenerimod effect on lymphocyte numbers, organ pathology, inflammation, and survival was evaluated in the MRL\/lpr lupus mouse model. Lymphocytes from healthy subjects and patients with SLE were assessed for cenerimod-induced S1P<jats:sub>1<\/jats:sub> receptor internalisation. Lymphocyte subsets and inflammatory biomarkers were characterised in a 12-week phase 2 clinical study (NCT-02472795), where patients with SLE were treated with multiple doses of cenerimod or placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"S2003\">\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>In MRL\/lpr mice treated with cenerimod, blood lymphocytes were reduced, leading to reduced immune infiltrates into tissue, and decreased tissue pathology, proteinuria, and inflammation, resulting in increased survival. Cenerimod was potent and efficacious in inducing S1P<jats:sub>1<\/jats:sub> receptor internalisation in lymphocytes in both healthy subjects and patients with SLE. In patients with SLE, 12-week cenerimod treatment resulted in a dose-dependent reduction of blood lymphocytes, antibody-secreting cells (ASC), and plasma IFN-\u03b1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"S2004\">\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>Cenerimod significantly ameliorated systemic and organ-specific pathology and inflammation in a mouse model of SLE. In lymphocytes from patients with SLE, the S1P<jats:sub>1<\/jats:sub> receptor remained functional despite concomitant background medication. The preclinical lymphocyte reduction translated to patients with SLE and resulted in the normalisation of ASC and the reduction of IFN-associated biomarkers. The efficacy and safety of cenerimod is being further investigated in a long-term clinical study in patients with SLE (CARE; NCT-03742037).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001261","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T10:55:19Z","timestamp":1599821719000},"page":"e001261","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Preclinical to clinical translation of cenerimod, a novel S1P<sub>1<\/sub> receptor modulator, in systemic lupus erythematosus"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0097-1937","authenticated-orcid":false,"given":"Daniel S","family":"Strasser","sequence":"first","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0558-9040","authenticated-orcid":false,"given":"Sylvie","family":"Froidevaux","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-3758","authenticated-orcid":false,"given":"Virginie","family":"Sippel","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4057-2903","authenticated-orcid":false,"given":"Estelle","family":"Gerossier","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9724-9563","authenticated-orcid":false,"given":"Ursula","family":"Grieder","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7691-9078","authenticated-orcid":false,"given":"Gabin M","family":"Pierlot","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9387-3294","authenticated-orcid":false,"given":"Andrea","family":"Kieninger-Graefitsch","sequence":"additional","affiliation":[{"name":"Inselspital Bern Universit\u00e4tsklinik F\u00fcr Kardiologie, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5550-9387","authenticated-orcid":false,"given":"Enrico","family":"Vezzali","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8525-758X","authenticated-orcid":false,"given":"Anna K","family":"Stalder","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7028-1915","authenticated-orcid":false,"given":"B\u00e9reng\u00e8re","family":"Renault","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1992-7298","authenticated-orcid":false,"given":"Jesper","family":"Ryge","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5805-822X","authenticated-orcid":false,"given":"Aaron","family":"Hart","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6026-0072","authenticated-orcid":false,"given":"Ulrich","family":"Mentzel","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8172-1752","authenticated-orcid":false,"given":"Peter M A","family":"Groenen","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-662X","authenticated-orcid":false,"given":"Marcel P","family":"Keller","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7036-8386","authenticated-orcid":false,"given":"Marten","family":"Trendelenburg","sequence":"additional","affiliation":[{"name":"Clinical Immunology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland"},{"name":"Division of Internal Medicine, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-3423","authenticated-orcid":false,"given":"Marianne M","family":"Martinic","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9735-7887","authenticated-orcid":false,"given":"Mark J","family":"Murphy","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"2025090313033868000_6.2.e001261.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071297"},{"key":"2025090313033868000_6.2.e001261.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.60"},{"key":"2025090313033868000_6.2.e001261.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.25032"},{"key":"2025090313033868000_6.2.e001261.4","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.10.5970"},{"key":"2025090313033868000_6.2.e001261.5","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3175"},{"key":"2025090313033868000_6.2.e001261.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.9.566"},{"key":"2025090313033868000_6.2.e001261.7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021553"},{"key":"2025090313033868000_6.2.e001261.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.20254"},{"key":"2025090313033868000_6.2.e001261.9","doi-asserted-by":"publisher","DOI":"10.1080\/08916930310001625952"},{"key":"2025090313033868000_6.2.e001261.10","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"16","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025090313033868000_6.2.e001261.11","first-page":"11","article-title":"Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus","volume":"3","author":"Chiba","year":"2006","journal-title":"Cell Mol Immunol"},{"key":"2025090313033868000_6.2.e001261.12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0264-y"},{"key":"2025090313033868000_6.2.e001261.13","first-page":"1","article-title":"Siponimod in the treatment of multiple sclerosis","volume":"3","author":"Goodman","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"2025090313033868000_6.2.e001261.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.02.009"},{"key":"2025090313033868000_6.2.e001261.15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/prp2.370","article-title":"Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties","volume":"5","author":"Piali","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"2025090313033868000_6.2.e001261.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew400"},{"key":"2025090313033868000_6.2.e001261.17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364286"},{"key":"2025090313033868000_6.2.e001261.18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.40792","article-title":"Monitoring disease activity in systemic lupus erythematosus with single-molecule array digital enzyme-linked immunosorbent assay quantification of serum interferon-alpha","volume":"71","author":"Mathian","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313033868000_6.2.e001261.19","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1136\/annrheumdis-2018-213497","article-title":"Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome","volume":"77","author":"van den Hoogen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090313033868000_6.2.e001261.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030491","article-title":"Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus","volume":"3","author":"Bauer","year":"2006","journal-title":"PLoS Med"},{"key":"2025090313033868000_6.2.e001261.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.24803"},{"key":"2025090313033868000_6.2.e001261.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.34483"},{"key":"2025090313033868000_6.2.e001261.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.27221"},{"key":"2025090313033868000_6.2.e001261.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.022681"},{"key":"2025090313033868000_6.2.e001261.25","doi-asserted-by":"publisher","DOI":"10.1038\/ni829"},{"key":"2025090313033868000_6.2.e001261.26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2016.07.002","article-title":"DNA-reactive B cells in lupus","volume":"43","author":"Suurmond","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"2025090313033868000_6.2.e001261.27","doi-asserted-by":"publisher","DOI":"10.1191\/0961203304lu1023oa"},{"key":"2025090313033868000_6.2.e001261.28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cytogfr.2016.02.003","article-title":"The light and the dark sides of interleukin-10 in immune-mediated diseases and cancer","volume":"30","author":"Geginat","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"2025090313033868000_6.2.e001261.29","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000354","article-title":"First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study","volume":"6","author":"Hermann","year":"2019","journal-title":"Lupus Sci Med"},{"key":"2025090313033868000_6.2.e001261.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.04057.x"},{"key":"2025090313033868000_6.2.e001261.31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41584-019-0235-5","article-title":"New therapies for systemic lupus erythematosus \u2013 past imperfect, future tense","volume":"15","author":"Murphy","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313033868000_6.2.e001261.32","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","article-title":"Management strategies and future directions for systemic lupus erythematosus in adults","volume":"393","author":"Durcan","year":"2019","journal-title":"Lancet"},{"key":"2025090313033868000_6.2.e001261.33","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bbrc.2010.03.078","article-title":"FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice","volume":"394","author":"Ando","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"2025090313033868000_6.2.e001261.34","first-page":"707","article-title":"Effects of FTY720 in MRL-lpr\/lpr mice: therapeutic potential in systemic lupus erythematosus","volume":"29","author":"Okazaki","year":"2002","journal-title":"J Rheumatol"},{"key":"2025090313033868000_6.2.e001261.35","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.396"},{"key":"2025090313033868000_6.2.e001261.36","doi-asserted-by":"crossref","first-page":"5821589","DOI":"10.1155\/2019\/5821589","article-title":"Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 modulator, potently inhibits the progression of lupus nephritis in two murine SLE models","volume":"2019","author":"Sugahara","year":"2019","journal-title":"J Immunol Res"},{"key":"2025090313033868000_6.2.e001261.37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193236","article-title":"Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus","volume":"13","author":"Taylor Meadows","year":"2018","journal-title":"PLoS One"},{"key":"2025090313033868000_6.2.e001261.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.03.008"},{"key":"2025090313033868000_6.2.e001261.39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2016.08.003","article-title":"Human effector B lymphocytes express ARID3a and secrete interferon alpha","volume":"75","author":"Ward","year":"2016","journal-title":"J Autoimmun"},{"key":"2025090313033868000_6.2.e001261.40","first-page":"21","article-title":"Role of production of type I interferons by B cells in the mechanisms and pathogenesis of systemic lupus erythematosus","volume":"25","author":"Hamilton","year":"2018","journal-title":"Discov Med"},{"key":"2025090313033868000_6.2.e001261.41","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090313033868000_6.2.e001261.42","doi-asserted-by":"publisher","DOI":"10.1186\/ar3433"},{"key":"2025090313033868000_6.2.e001261.43","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2025090313033868000_6.2.e001261.44","doi-asserted-by":"publisher","DOI":"10.1038\/nri3795"},{"key":"2025090313033868000_6.2.e001261.45","doi-asserted-by":"crossref","first-page":"16428","DOI":"10.1038\/s41598-017-16681-y","article-title":"Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus","volume":"7","author":"Sakakibara","year":"2017","journal-title":"Sci Rep"},{"key":"2025090313033868000_6.2.e001261.46","doi-asserted-by":"publisher","DOI":"10.1002\/art.10949"},{"key":"2025090313033868000_6.2.e001261.47","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.celrep.2018.06.046","article-title":"B-cell-intrinsic type 1 interferon signaling is crucial for loss of tolerance and the development of autoreactive B cells","volume":"24","author":"Domeier","year":"2018","journal-title":"Cell Rep"},{"key":"2025090313033868000_6.2.e001261.48","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00109-016-1421-4","article-title":"Cause and consequences of the activated type I interferon system in SLE","volume":"94","author":"Eloranta","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"2025090313033868000_6.2.e001261.49","first-page":"1","article-title":"A phase 3 randomized controlled trial of anifrolumab in patients with moderate to severe systemic lupus erythematosus","volume":"71","author":"Furie","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313033868000_6.2.e001261.50","first-page":"635","article-title":"The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases","volume":"6","author":"Khan","year":"2015","journal-title":"Front Immunol"},{"key":"2025090313033868000_6.2.e001261.51","doi-asserted-by":"crossref","unstructured":"Haynes WA , Haddon DJ , Diep V , et al. Integrated, multi-cohort analysis reveals unified signature of systemic lupus erythematosus. JCI Insight 2020 Jan 23. doi: 10.1172\/jci.insight.122312","DOI":"10.1172\/jci.insight.122312"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:03:54Z","timestamp":1756929834000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,9,11]]},"published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1136\/rmdopen-2020-001261"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001261","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}